Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-348 · 2 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| Monotherapy, once daily | EXPERIMENTAL | - |
| Monotherapy, twice daily | EXPERIMENTAL | - |
| Combination with Azacitidine | EXPERIMENTAL | - |
| IV monotherapy, once daily | EXPERIMENTAL | - |
| Combination with carboplatin | EXPERIMENTAL | - |
| Combination with docetaxel | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ABT-348 | DRUG | An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle. |
| ABT-348 and azacitidine | DRUG | An oral dose of ABT-348 on Day 1, Day 8, and Day 15 of each 28 day cycle. An IV or injection of azacitidine on Days 1-7 of each 28 day cycle. |
| ABT-348 and carboplatin | DRUG | An oral dose of ABT-348 will begin in Cycle 2on Day 1 and Day 8; and an IV dose of carboplatin (AUC 5.0) on Day 1 of each 21-day cycle. |
| ABT-348 and docetaxel | DRUG | ABT-348 dosing will begin in Cycle 2. An oral dose of ABT-348 on Day 1 and Day 8; and an IV dose of docetaxel (75 mg/m2) on Day 1 of each 21-day cycle. |
Inclusion Criteria: 1. Histological or cytological confirmation of one of the following (Arms A, B and D): * Relapsed or refractory acute myelogenous leukemia (AML), untreated AML in subjects who are \> 60 years of age and do not have favorable cytogenetics (i.e., lack t(8,21) or inv(16)/t(16,1...
ABT-348 is an investigational small molecule being studied for the treatment of advanced solid tumors and acute lymphoblastic leukemia. It is also being evaluated in other hematologic malignancies, including acute myelogenous leukemia, B-cell chronic lymphocytic leukemia, chronic myelogenous leukemia, and myelodysplasia.
ABT-348 is being developed by AbbVie Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker ABBV. The drug is currently in Phase 1 clinical development for oncology indications.
ABT-348 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed, but the drug remains under study for the treatment of advanced solid tumors and hematologic malignancies.
ABT-348 has been studied in two completed Phase 1 clinical trials. NCT01110473 evaluated ABT-348 as monotherapy and in combination with azacitidine for advanced hematologic malignancies. NCT01110486 evaluated ABT-348 as monotherapy or in combination with carboplatin or docetaxel for advanced solid tumors.
ABT-348 is the primary name for this investigational small molecule. No alternative names have been reported for this drug in clinical trial records.